Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Trial of Combination Immunotherapy With Nelipepimut-S + GM-CSF (NeuVax) and Trastuzumab in High-risk HER2+ Breast Cancer Patients

Trial Profile

Phase II Trial of Combination Immunotherapy With Nelipepimut-S + GM-CSF (NeuVax) and Trastuzumab in High-risk HER2+ Breast Cancer Patients

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nelipepimut-S (Primary) ; Sargramostim (Primary) ; Trastuzumab (Primary)
  • Indications Advanced breast cancer; Early breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Jun 2019 Data from a preplanned analysis of this trial presented in a Sellas Life Sciences Group Media Release.
    • 03 Jun 2019 According to a Sellas Life Sciences Group media release, data from a preplanned analysis of this trial was presented on June 2, 2019 at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO).
    • 15 May 2019 According to a Sellas Life Sciences Group media release, immunologic response data from this study will be presented at the upcoming ASCO Annual Meeting (May 31st-June 4th, 2019 in Chicago, IL).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top